Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors

Acquisition Expected to Complement and Add Material Sales to Company's Dx Business

Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced the acquisition of all of the key assets of Pathwork Diagnostics, including its FDA-cleared, Medicare-reimbursed test for the diagnosis of metastatic, poorly differentiated and undifferentiated cancer.

Terms of the deal include a $200,000 cash payment and issuance of 500,000 shares of Response Genetics common stock with a lock-up period through June 2014. The Company expects the deal to be accretive within its first full year of acquisition.

Response Genetics, Inc. Announces Contract With MultiPlan, Inc.

Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has entered into an agreement with MultiPlan, Inc., the industry's most comprehensive provider of healthcare cost management solutions.

As a participating provider in the PHCS and MultiPlan Networks, MultiPlan's clients will now have access to all of Response Genetics' molecular diagnostic testing. Response Genetics specializes in predictive genomic testing that supplies treating physicians with actionable information helping the physicians determine what drugs will have the greatest response from each of their patients battling lung, colorectal, gastric and melanoma cancers.

OraSure Announces 2013 Second Quarter Financial Results

OraSure Technologies, Inc. (OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2013.

Financial Highlights

• Consolidated net revenues for the second quarter of 2013 were $24.3 million, an 8% increase from the comparable quarter of 2012. Consolidated net revenues for the six months ended June 30, 2013 were $45.5 million, a 4% increase from the comparable period of 2012. During the quarter and the six month period, net product revenues increased 8% and 7%, respectively.

  Published: 08 August 2013

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: OraSure Technologies Inc ( OSUR )

Urine-based Cancer Detection Technology Validate

Trovagene develops ultra-sensitive cell-free DNA assay

Trovagene, Inc. (TROV) announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen.

The ability to regularly detect and monitor the results of cancer treatment through a non-invasive, systemic sample could significantly help patients who require therapy for recurrent or metastatic cancer.